Kura Oncology Reports Final Results from Phase 2 Study of Tipifarnib in T-Cell Lymphoma | Traderszone

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 13 December, 2021 by The TZ Newswire Staff

Kura Oncology Reports Final Results from Phase 2 Study of Tipifarnib in T-Cell Lymphoma

– Overall response rate of 56% and median overall survival of 32.8 months in patients with advanced AITL, an aggressive form of T-cell lymphoma –

See also
- Next Article Seedo Corp Announces A Change In The Company’s Name To SATIVUS TECH CORP And The Appointment Of a CEO For Its Israeli Subsidiary, Saffron Tech
- Previous Article Year-end bonuses are back! Here’s what to do with yours
Editorial Calender

December 2021

M T W T F S S

1 2 3 4 5

6 7 8 9 10 11 12

13 14 15 16 17 18 19

20 21 22 23 24 25 26

27 28 29 30 31

« Nov Jan »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar